Objectives: In this study, we present our mid-term outcomes on redo transcatheter aortic valve implantation (TAVI). Patients and methods: Between June 2012 and May 2019, a total of eight TAVI-in-TAVI patients (2 males, 6 females; mean age: 73.83.9 years; range, 66 to 79 year) were retrospectively analyzed. All patients were evaluated for comorbidity, characteristics of the first TAVI valve, indications for redo-TAVI, transthoracic echocardiographic parameters, mortality, pacemaker requirement, and valve function during follow-up. Results: Five (62.5%) of the patients required a redo-TAVI procedure due to severe aortic regurgitation, while three (37.5%) required a redo-TAVI procedure due to degeneration of the first TAVI valve. The first TAVI valves of the patients were two Portico™, four CoreValve™ and two Edwards SAPIEN™. In redo-TAVI procedures of the patients, four CoreValve™, two Portico™, and two MyVal™ valves were used. The median time after the first procedure was 62 months. One patient had hypertensive pulmonary edema during the procedure and was intubated, and in-hospital mortality occurred due to infectious causes during intensive care follow-up. There was no in-hospital mortality and no need for pacemaker in other patients. There was no mortality at a median follow-up of 31 months after redo-TAVI procedures. Conclusion: Redo-TAVI procedure is a feasible intervention and can be successfully done in selected patients requiring reintervention due to valve degeneration or severe aortic regurgitation.
